PDCD1 and Miyoshi myopathy: Despite at first, in vitro and in vivo studies showed that PD-1/PD-L1 blockade enhanced T and NK cell mediated anti-myeloma immune responses (42, 64, 86, 139–141) suggesting that ICP inhibition may be a promising therapeutic strategy against MM, clinical trials have provided unsatisfactory results (125).